Antibody Discovery Services
Discover diverse, high-affinity, developable antibodies through in vitro selection
Specifica’s Generation 3 platform combines phage display, yeast display, next-generation sequencing and guided selection to discovery diverse, target-specific antibody leads. We deliver drug-like antibodies straight from selections—bringing developability considerations into design from the start and reducing the need for downstream optimization.
Our Approach to In Vitro Antibody Discovery
Successful antibody discovery programs must balance four competing requirements: affinity, specificity, developability and diversity. Our in vitro selections from naïve libraries are designed to allow rapid and direct selection for specific properties of interest, rather than just generic binders. Our technical team collaborates with the customer throughout the process, adjusting as needed to ensure we meet your goals.
Our approach delivers:
-
-
Speed to a promising lead candidate
-
Antibodies against challenging target epitopes
-
Identification of multiple distinct antibody families
-
Reduced downstream optimization requirements
-
Greater confidence when advancing candidates toward development
-
Our formats include VHH, scFv-IgG, and constant light chain libraries. The outputs can be reformatted to any format desired by the customer, including Fab, custom Fc, VHH-Fc, KiH bi-specifics, etc. for final validation of affinity and binding properties.
Gen 3 Antibody Discovery Performance
Each column represents leads from a campaign against a unique target.
Black - ScFv
Green - peptide MHC
Blue - VHH
100+ antibody programs completed
>80% of leads have no measurable biophysical liabilities
Formats include scFv-IgG, VHH, constant light chain
9 of the top 20 pharma companies are customers
scFv Antibody Discovery
Specifica’s Generation 3 single-chain variable fragment (scFv) libraries are built on validated therapeutic scaffolds with proven developability. While the libraries and built and selected as scFv, the scaffolds are specifically chosen based on their excellent ability to reformat to functional IgGs. Discovery campaigns use integrated phage and yeast display to select diverse antibodies with the affinity, specificity and biological properties required for your therapeutic program.
-
- High affinity – High-affinity antibodies directly from de novo discovery, reducing or eliminating the need for subsequent affinity maturation.
- >75% of scFv campaigns, excluding pMHC campaigns, yield at least one sub-nanomolar binder
- >20% of scFv binders are sub-nanomolar, with 60% of antibodies having affinities below 10 nM.
- Exceptional diversity – Large naïve libraries incorporating more than 1018 unique, naturally derived HCDR3s enable discovery of broad panels of antibodies targeting diverse epitopes. NGS analysis can identify hundreds of distinct antibody clusters from selection outputs.
- Designed for developability – Gen 3 libraries use therapeutic antibody scaffolds and natural CDR diversity, with sequence liabilities removed from 5 of the 6 CDRs. More than 80% of antibodies characterized from the platform have no measurable biophysical liabilities.
Select for the biology you need – Our integrated phage and yeast display workflow allows antibodies to be selected, rather than simply screened, for properties such as species cross-reactivity, domain and epitope specificity, affinity, ligand competition, and more. - Broad sequence and epitope diversity – NGS combined with sequence clustering enables identification of large numbers of distinct antibody families, increasing the opportunity to discover antibodies with differentiated binding and biological properties.
- Fast, fully in vitro discovery – Rapid discovery without the timelines or biological constraints of an immunization campaign.
- Read about scFv antibody discovery success in this article in mAbs.
- High affinity – High-affinity antibodies directly from de novo discovery, reducing or eliminating the need for subsequent affinity maturation.
Discuss your Project
Gen 3 Platform VHH Projects
Each column represents a unique target.
VHH / single-domain antibody discovery
Specifica’s VHH libraries are built on therapeutic scaffolds and designed to combine broad diversity with developability, allowing flexible design of a de novo discovery campaign fully in vitro, without requiring an immunization step.
-
- Higher rate of success – our approach is also successful when homology between a human and camelid target is high, a scenario where immunization approaches often fail
-
Broad diversity – our phage display libraries far exceed the diversity of immunization, and sorting via yeast display provides additional capabilities to enable selection for desired properties
-
High affinity:
-
-
>50% of campaigns yield at least one sub-nanomolar binder
-
>50% of binders <10nM and ~5% of binders are sub-nanomolar
-
-
-
High specificity – controlled selection conditions allow you to focus on specific regions of your target antigen
-
Developability – >70% of VHHs have two or fewer biophysical liabilities
-
More human than humanized VHHs – fully human CDRs within humanized frameworks help reduce downstream engineering through improved safety and therapeutic efficacy
Read about our success in developing single-domain (VHH) antibodies from our libraries in this 2025 article in mAbs.
What are the advantages of VHH antibodies?
-
VHHs are single-domain proteins based on camelid antibodies.
-
VHHs are much smaller than traditional antibodies, enabling them to bind to challenging targets including “hidden” epitopes less easily accessible by traditional antibodies.
-
VHHs are becoming increasingly common as building blocks in bi- and multi-specific chimeric antibodies, highlighting the importance in the therapeutic space.
-
VHHs are stable and soluble, supporting consistent quality and reduced variability.
What is Specifica's approach to VHH discovery?
- Our VHH libraries are based on four well-behaved therapeutic VHH molecules, with HCDR1 and 2 natural replicated diversity from rearranged VH3 family genes, and void of sequence liabilities.
- The CDRs are filtered for correct folding via protein A selection (protein A binding being an inherent property of the VH3-23 gene family)
- Only well-folded CDRs are allowed in the final library, enhancing its functionality and overall quality.
Flexible Antibody Discovery Without Royalties
Specifica can support a single discovery campaign or build a custom library for customers who want to keep discovery in-house. Our fee-for-service model avoids royalties or milestone-based fees. You retain the rights to develop antibodies from your campaigns or purchased libraries. A robust gatekeeping process ensures that each client receives unique, first-tier leads.
Specifica, an IQVIA business
Specifica was acquired by IQVIA Laboratories in 2022 and opened a second lab at IQVIA headquarters in 2026.
Our customers can access expanded capabilities through IQVIA Laboratories Discovery Sciences, including downstream services as their programs advance.